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M u s c u l o s k e l e t a ls y s t e mi sac o m p l e xa s s e m b l yo ft i s s u e sw h i c ha c t sa ss c a ﬀold for the body and enables locomotion. It is often
overlooked that diﬀerent components of this system may biomechanically interact and aﬀect each other. Skeletal dysplasias are
diseases predominantly aﬀecting the development of the osseous skeleton. However, in some cases skeletal dysplasia patients are
referred to neuromuscular clinics prior to the correct skeletal diagnosis. The muscular complications seen in these cases are usually
mild and may stem directly from the muscle defect and/or from the altered interactions between the individual components
of the musculoskeletal system. A correct early diagnosis may enable better management of the patients and a better quality of
life. This paper attempts to summarise the diﬀerent components of the musculoskeletal system which are aﬀected in skeletal
dysplasias and lists several interesting examples of such diseases in order to enable better understanding of the complexity of
human musculoskeletal system.
1.Introduction
Skeletal dysplasias are a diverse group of diseases primarily
aﬀecting the development of the osseous skeleton. They
manifest with disproportionate short stature, malforma-
tions, and/or deformations and range from relatively mild
to severe and lethal conditions. To date there are over
250 unique and well-characterised skeletal dysplasias, many
of which can be grouped into diﬀerent diagnostic groups
and/or bone dysplasia families based on clinical similarities
[1]. It is important to note that skeletal dysplasia mutations
may also inﬂuence other nonskeletal organs, often mechan-
ically by tightening the tracts in the body due to skeletal
defects. For example, children with skeletal dysplasias often
have respiratory problems and mental problems sometimes
occur due to craniofacial defects[2]. Early diagnosis of skele-
taldysplasiasisthereforecrucialforpatientmanagementand
may enable relatively normal growing up and life span.
Skeletal dysplasias may sometimes be associated with
muscular disorders. Skeletal muscle, tendon and ligament,
and the bones themselves form a complicated biomechanical
system of levers and forces; therefore, abnormalities in one
tissuemaypotentiallyaﬀecttheothers.Itisknownthatbones
reactandremodelaccordingtotheforcesexertedbymuscles.
Tendons and ligaments also repair and remodel according to
the biomechanical forces exerted upon them. Therefore, for
the wellbeing of the patient, it is important to recognise all
the tissues that the disease may be aﬀecting. In this paper
we summarise the relationships between diﬀerent tissues
in the musculoskeletal system and discuss several skeletal
dysplasias in which muscle and/or tendon weakness has been
recognised and described. This detailed paper will provide
betterunderstandingofthemusculoskeletalbiologyandmay
enable better diagnosis and management of the patients in
future.
2. Biomechanics of the MusculoskeletalSystem
2.1. Bones and Growth Plate Cartilage. Bone is a hard
connective tissue consisting of osteocytes embedded in an
abundantextracellularmatrix(ECM).Bonesactasascaﬀold,
attachment points, leverage, and protection for soft tissues.2 Journal of Biomedicine and Biotechnology
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Figure 1: (a) A schematic representation of processes that may
inﬂuence bone formation and resorption [3]. (b) A graph illustrat-
ing the Hueter-Volkman law [4].
During life, and to enable growth, repair and mineralisation,
the bone is constantly being remodelled by osteoblasts and
osteoclasts [5]. Furthermore, bone is a dynamic tissue which
is able to remodel in response to the mechanical load. For
example, an increase in loading bone formation increases
and resorption decreases whilst unloading of the bone has
an opposite eﬀect (Figure 1(a))[ 3].
The human skeleton consists of 206 bones of diﬀering
shapes and functions and distributed throughout the entire
body [6]. Surprisingly, however, this complicated scaﬀolding
is formed by only two distinct and very conserved processes
[7]. Both processes begin with mesenchymal condensation.
Bones of the craniofacial skeleton evolve from migrating
neural crest cells in a process called intramembranous ossi-
ﬁcation. The rest of the skeleton is formed by mesenchymal
cells forming a cartilage anlagen, which is later replaced by
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Figure 2: A histological H&E (haematoxylin and eosin) stained
image of an adult mouse growth plate and a schematic representa-
tionofdiﬀerentiationzonesinthetissue.Inthegrowthplateseveral
distinct structural zones can be identiﬁed, reﬂecting the gradual
transition of cells through diﬀerent stages of diﬀerentiation [13].
Resting zone acts as a reserve of precursor cells for the proliferating
chondrocytes in the columns [10]. Proliferating zone is where the
cells ﬂatten and divide, laying down a cartilage extracellular matrix
that will later serve as a scaﬀold for bone formation [14]. In the
prehypertrophiczone,thecellsenterthematurationzoneandbegin
to enlarge. In the hypertrophic zone, the chondrocytes and their
lacunae become 5–12 times bigger [14]. These cells eventually die,
triggering vascularisation and bone formation.
bone in endochondral (i.e., “in cartilage”) ossiﬁcation [8].
Both ossiﬁcation pathways are also implicated in bone repair
at later stages of life, with intramembranous ossiﬁcation
being the method of repair for stabilised fractures, whilst
unstable fractures heal via endochondral ossiﬁcation [9].
These separate pathways share many common regulatory
genes and proteins, local paracrine regulators, blood stream
hormones, and transcription factors [10]. Mechanical forces
are also extremely important for proper development of the
skeleton, inﬂuencing the shape of the bones, their repair
processes, and signalling pathways [11, 12].
Limb development begins with the condensation of
mesenchyme after which the cells diﬀerentiate into chon-
drocytes, which form the cartilaginous template [7]. As the
cartilage grows, the cells are forced apart by the extracellular
matrix and become encapsulated in the thickening matrix.
Meanwhile, within the cartilage anlagen, the encapsulated
cells die due to their intensive growth and calcium salt
deposition, and the ECM eventually erodes [15]. The blood
vessels invade the cartilage, bringing bone-forming cells,
which diﬀerentiate into osteoblasts and secrete additional
extracellular matrix. This matrix is subsequently calciﬁed
forming trabeculae, some of which are later reabsorbed by
the osteoclasts thus forming a bone marrow cavity [16]. As
the bones continue to grow, a secondary ossiﬁcation centre
is established in the epiphyses [10] and between the shaft
of the bone and the epiphysis a cartilage growth plate is
formed (Figure 2), allowing longitudinal bone growth. TheJournal of Biomedicine and Biotechnology 3
thickening of bone is achieved by depositing further layers
on the periosteum side by osteoblasts, and widening of the
bone marrow cavity by osteoclasts. Eventually, the epiphysis
and metaphysis in the bone fuse, usually around puberty,
forming a diaphyseal mature bone [11].
Growth plate cartilage extracellular matrix is composed
of type II collagen ﬁbers and is abundant in proteoglycans,
speciﬁcally aggrecan. This makes it a relatively compliant
tissue and so it is able to respond to mechanical and
gravity forces. To a certain extent, growing bones are able
to align themselves according to the gravity forces exerted
upon them, as can be seen in the correction of a mild
genu varum in toddlers [17]. However, strong compression
inhibits bone growth and tension has an opposite eﬀect by
increasing growth in bone length [4, 18]. This is known as
the Hueter-Volkman law (Figure 1(b)), which was further
deﬁned by Frost in the twentieth century and is often used by
clinicians in surgical correction of certain limb deformities
[4, 17]. Lack of mechanical loading also results in decreased
bone formation, as shown by weightlessness and suspension
experiments (Figure 1(a))[ 19–21].
Gravity induced mechanosensing in the growth plate
cartilage is achieved by a microtubule-based organelle called
the primary cilium [22–24]. Primary cilia are cytoplas-
matic protrusions that are associated with many proteins
implicated in signal transduction, speciﬁcally integrins and
extracellularmatrixreceptors,andenablethecellstorespond
to mechanical stimuli [22] .T h e ye x i s to na l m o s te v e ryc e l li n
the human body and are very important for mechanosensing
and biomechanics of many diﬀerent tissues.
2.2. Articular Cartilage. Cartilage is a highly specialised con-
nective tissue. Its mechanical properties allow it to withstand
compressiveforcesandalsotoasmallerextentresistshearing
and torsional forces [5]. Cartilage consists mostly of an
extracellular matrix and its structure varies according to
species, location, and age of the tissue [5]. Hyaline cartilage
is the most abundant type of cartilage. It is a precursor
to the growth plate (physis), and it is also found at the
articular surface of bones, where it acts as a shock absorber
and protection for the underlying subchondral bone [25].
Chondrocytes in the hyaline cartilage are ovoid, ranging in
shape from round to ﬂat [5]. Each chondrocyte occupies a
space (lat. lacuna) encapsulated by the extracellular matrix,
which is important for cartilage biomechanical properties.
Chondrocyte together with its pericellular matrix is often
termed “chondron” [26]. It has been shown that pericellular
matrix of articular cartilage has a precise macromolecular
architecture, with a high content of proteoglycans, such as
aggrecan, embedded in the collagen matrix [27]. Aggrecan
retains water, thus contributing to the cartilage tissue elastic-
ity [28]. The shape of individual chondrons is also important
and they respond to the gravitational forces by producing a
compact matrix “cap” pointing towards the surface of the
tissue and a looser “tail” extending into the ECM below
[27].Chondrons have oftenbeen referred to as ﬂuid bladders
and indeed they seem to function in a similar manner [29].
When cartilage is subjected to compression, the liquid is
pushed out of the proteoglycan complex and the collagen
rich matrix deforms, thus increasing the pressure within the
chondron. This change in osmotic pressure due to escaping
water protects the chondrocyte and enables its full recovery
at unloading [29]. Chondrocytes also have a primary cilium
which helps them sense these changes in forces [22, 23, 26].
This seems to be especially important in the aetiology and
management of osteoarthritis where even a ligamentous
instability or a weakness of periarticular muscles, and
therefore an abnormal biomechanical environment, may
result in joint degeneration [30, 31].
2.3. Entheses (at the Bone to Tendon Junction). Fibrocartilage
is an intermediate tissue between the hyaline cartilage and
dense ﬁbrous tissues [5, 32]. It only has a few chondrocytes
in the lacunae, and its matrix contains many thick collagen
ﬁ b r e sa r r a n g e di na no r d e r e df a s h i o n .I tc a nb ef o u n di n
invertebral discs, symphysis pubis, articular disc of the stern-
oclavicularandtemperomandibularjoints,themenisciofthe
knee joints, and places where ligaments or tendons attach to
bones and is formed as tendon’s reaction to compressive load
[33]. Fibrocartilage is associated with epiphyseal tendons
and ligaments and is important in force transduction as
it dissipates the stress on the tendon ﬁbers near the bone
[32, 34, 35]. Its molecular composition is similar to that of
tendon, but several cartilage speciﬁc molecules, such as type
II and type IX collagen and aggrecan, are also present in the
matrix [33].
2.4. Tendon and Ligament. Tendon (Figures 3(a) and 3(b) )
and ligament are soft collagenous tissues, linking muscle to
bone and bone to bone, respectively. They consists of densely
packed bundles of ﬁbrous collagen and are characterised
by high tensile strength and elasticity [5]. Tendon and
ligament both have similar hierarchical structure, consisting
of fascicles, which are built of smaller basic ﬁbrils and
ﬁbroblasts [36]. The main component of the basic ﬁbril is
type I collagen. Both ligaments and tendons are surrounded
by a sheath of transparent material called the synovial mem-
brane, a delicate connective tissue layer secreting synovium,
a viscous lubricating ﬂuid [5].
Tendons act as buﬀers and storage of elastic kinetic
energy during walking [37]. They can remodel according to
the forces exerted upon them [34, 38]. It has been shown
that the immobilisation of limbs leads to a decrease in
collagen turnover in the tendon and a decrease in tendon
diameters [39], and conversely, exercise leads to an increase
in tendon diameter and collagen turnover [40]. Increase
in tendon diameters correlates with an increase in the
stiﬀness of the tissue [38], which means thicker tendons
can withstand higher tensile forces exerted upon them by
stronger muscles. Tendons also become thicker and less
c o m p l i a n tw i t ha g e[ 37], which together with age-associated
muscle wasting helps explain the weakness and diﬃculties in
walking experienced by the elderly [41].
2.5. Myotendinous Junction and Perimysium. Another struc-
ture that is biomechanically important for conveying forces
from muscle to tendon is the myotendinous junction (MTJ;
Figure 4). This is the site where tendon meets, and merges,4 Journal of Biomedicine and Biotechnology
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Figure 3: (a) A schematic representation of tendon hierarchical structure and a transmission electron microscopy image of a tenocyte
embedded in the collagen matrix. (b) A histological (Gomori trichrome, staining collagenous tissues blue) image of a longitudinal section
of patellar tendon showing parallel running collagen bundles in the tissue.
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Figure 4: Schematic representation of the skeletal muscle structure and histological images of a longitudinal section of murine skeletal
muscle and of murine Achilles tendon myotendinous junction (MTJ) stained with a trichrome Gomori stain to visualise collagenous tissues
(staining muscle red, collagenous tissues blue, and nuclei black).Journal of Biomedicine and Biotechnology 5
with the skeletal muscle and the point where muscle
contractile forces are transmitted to the tendon [42]. The
myotendinousjunctionmembraneisextensivelyfolded.This
means that the tensile stress exerted by the contracting
muscle ﬁbers becomes shear stress instead, thus increasing
the strength of the junction and protecting the tissues from
injury [42]. The myotendinous junction is also connected to
the collagenous perimysium surrounding the skeletal muscle
fascicles [43]. The perimysium forms a lattice structure
within the skeletal muscle and is involved in transmission
of lateral forces in the muscle. MTJ and perimysium are
together responsible for conveying the forces from muscle to
tendon [43, 44].
2.6. Skeletal Muscle. Skeletal muscle acts as the motor of the
body and is essential for locomotion. As such it has a very
complex hierarchical structure (Figure 4). Each myoﬁber is a
one multinuclear cell (with nuclei located to the periphery)
that often spans the length of the entire muscle. Most of
the myoﬁber is ﬁlled with contractile myoﬁbrils consisting
of actin and myosin and responsible for muscle contraction.
The discovery of costameres by Pardo et al. in 1983 showed
the ﬁrst direct link between the surrounding extracellular
matrix and the myoﬁbers [45]. Costameres are regularly
spaced around the Z-lines of the skeletal muscle and play
a role in lateral force transmission, as shown by single
myoﬁber studies performed by Street et al. [44, 46]. Every
m y o ﬁ b e ri sc o v e r e db yac o n n e c t i v et i s s u es h e a t hc a l l e d
the endomysium [47]. Groups of muscle ﬁbers are covered
by another connective tissue sheath called the perimysium,
which transmits the lateral forces between the muscle
bundles [48]. Not every myoﬁber spans the entire muscle
length and connects to the myotendinous junction; however,
all the ﬁbrous extracellular matrices are interconnected and
eventually lead to the myotendinous junction and to the
tendon itself [44]. Muscle can also remodel and adapt to the
mechanical load [49], and muscle hypertrophy is often seen
as a result of exercise [50].
3.SkeletalDysplasias:GeneticsDisorders
Affecting the Osseous Skeleton
Skeletaldysplasiasareagroupofskeletalandmusculoskeletal
diseases that aﬀect the development of the osseous skeleton.
There are over 250 well-characterised phenotypes known to
date, which aﬀect the development of both ﬂat and long
bones [51]. The many diﬀerent genes that are mutated in
skeletaldysplasiasspanawiderangeofcellularandmetabolic
processes and include those involved in the extracellular
matrix, metabolic pathways, folding and degradation of
macromolecules, hormones and signal transduction mecha-
nisms, nuclear proteins and transcription factors, oncogenes
andtumoursuppressorgenesandRNA,andDNAprocessing
and metabolism [52].
Many skeletal dysplasia phenotypes are characterised
by severe deformations and/or malformations of numerous
skeletal elements and with such conditions it is sometimes
easytooverlook otherclinicalaspects,suchastheeﬀectthese
skeletal abnormalities may have on the soft tissues of the
body [2]. Skeletal dysplasias may result in tightening of the
tracts in the body thus aﬀecting breathing and patient’s well-
being. Shorter limbs may result in a diﬀerent distribution of
biomechanical forces exerted by the muscles and thus may
contribute to diﬃculties in walking. Furthermore, many of
theextracellularmatrixgenesexpressedinboneandcartilage
and involved in skeletal dysplasias are also present in other
musculoskeletal tissues, such as muscle and tendon, and may
aﬀect patients’ well-being and quality of life.
4.SkeletalDysplasiasThatAre
AssociatedwithMyopathies
There are several skeletal dysplasia phenotypes in which
myopathyisarecognisedneuromuscularcomplicationofthe
disease. In some of the cases, the muscle pathology stems
directly from the fact that the mutant protein is expressed in
the muscle as well as in cartilage and bone, but in others the
eﬀect appears to be more indirect. A detailed analysis of the
muscular symptoms in these phenotypes is very important
since the neuromuscular complications often manifest prior
to the skeletal deformations, which may arise during pre-
pubertal growth, and therefore might allow quicker diag-
nosis and better management of the patient. We present
a short summary of these conditions below and also in
Table 1.
4.1. Multiple Epiphyseal Dysplasia: An Indirect ECM Defect?
Multiple epiphyseal dysplasia (MED) is a skeletal dysplasia
in which an associated myopathy has only recently been
recognised and reported in patients [53–55]. MED belongs
to a “bone dysplasia family” that also includes the related
and more severe disease known as pseudoachondroplasia
(PSACH) [51, 56]. Together these phenotypes form a
distinct spectrum of disease severity ranging from a mild
MED through to severe PSACH at the other end of the
spectrum. The PSACH-MED phenotype is characterised
by disproportionate short stature, lower limb deformations
(genu varum and genu valgum), joint laxity, and early onset
degenerative joint disease [57]. Radiographic features of
PSACH manifest in the epiphyses and the metaphyses of
the long bones and in MED are restricted to the epiphyses
[58]. PSACH and the more severe forms of MED result from
mutations in the gene encoding cartilage oligomeric matrix
protein (COMP), a pentameric ECM bridging molecule
found in cartilage, tendon, ligament, and skeletal muscle
[59]. PSACH-MED mutations in COMP cluster in the
exons encoding the calcium-binding thrombospondin type
3 repeats (T3) and the C-terminal domain (CTD) of COMP.
In chondrocytes the expression of these mutations results in
various levels of endoplasmic reticulum (ER) stress and cell
death [59, 60]. A role for COMP in collagen ﬁbrillogenesis
has been proposed and it is thought to be one of the
catalysts of this process [61]. Furthermore, in the cartilage
extracellular matrix COMP plays a bridging role and is able
to interact with other ECM molecules such as matrilin-3,
type IX collagen, aggrecan, ﬁbronectin, and integrins [62–
65]. It is therefore not surprising that other MED-causing6 Journal of Biomedicine and Biotechnology
Table 1: Summary of the published skeletal dysplasias associated with a mild myopathy phenotype.
Disease name Multiple epiphyseal
dysplasia (MED)
Multiple epiphyseal
dysplasia (MED)
Camurati-Englemann
disease (CED)
Marfan syndrome
(MFS1)
Schwartz-Jampel
syndrome (SJS1)
Alternative
name EDM3 EDM1 Progressive diaphyseal
dysplasia
Chondrodystrophic
myotonia
Mode of
inheritance Autosomal dominant Autosomal dominant Autosomal dominant Autosomal dominant Autosomal recessive
Gene COL9A3 COMP TGF-β1 Fibrilin-1 Perlecan
Skeletal
symptoms
Epiphyseal dysplasia,
early onset degenerative
joint disease (knees),
mild or no short limbed
dwarﬁsm
Epiphyseal dysplasia,
early onset
degenerative joint
disease, mild short
limbed dwarﬁsm
Thicker bone
diaphyses, thicker
bones of the skull,
tighter bone canals,
bone pain,
hyperlordosis,
scoliosis
Increased height,
scoliosis, thoracic
lordosis, highly
arched palate with
tooth crowding
Short femurs, short
stature, micrognathia,
kyphoscoliosis, joint
deformities, coxa
valga, irregular capital
femoral epiphyses
Skeletal onset Childhood ∼3 years ∼3 years Childhood <3 years, muscle
stiﬀness after birth
Muscular
symptoms
Mild muscle weakness,
diﬃculty rising form the
ﬂoor
Muscle weakness, easy
fatigue, diﬃculty
rising form the ﬂoor
Easy fatigue, proximal
muscle weakness and
atrophy, waddling gait
Mild to moderate
joint laxity, muscle
weakness, muscle
atrophy, hypoplasia,
cannot increase
muscle mass in
response to exercise
Mild largely
non-progressive
muscle weakness,
stiﬀness, myotonic
myopathy, waddling
gait, crouched stance,
hypertrophy, reduced
tendon reﬂexes, joint
contractures
CK levels Mildly elevated Normal or mildly
elevated Elevated up to 40% Normal or mildly
elevated
Normal or mildly
elevated
Muscle
biopsy
Mild myopathy, a slight
variability in ﬁber size
No variability in ﬁber
size, scattered
basophilic ﬁbers
and/or small atrophic
ﬁbers
Often normal,
occasional variability
in ﬁber size
Sometimes myopathic
changes seen,
abnormalities in
ﬁbrilin-1
immunoreactivity
Central nuclei, varied
ﬁber size, changes of
ﬁber type
Muscle
electron
microscopy
——
Thicker basement
membrane around
the blood vessels, few
ﬁbers with
accumulated
mitochondria
——
EMG — —
Short small action
potentials in some
muscles, myopathic
Myopathic and
neurogenic
Myotonic
abnormalities
Other
aﬀected
tissues
——
Liver, spleen, gonads
(hepatosplenomegaly
and hypogonadism)
Eyes: myopia, ectopia
lensis, corneal ﬂatness
Eyes: myopia,
blepharophimosis
Possible
therapy Not available Not available Corticosteroids
Lasartan (aortic
aneurism, and muscle
involvement)
Reducing muscle
stiﬀness,
anticonvulsants and
antiarrhythemics
mutations were found in genes encoding proteins known to
interact with COMP such as matrilin-3 and type IX collagen,
although the precise rationale for this genetic heterogeneity
of MED has yet to be determined.
Until recently, PSACH-MED has primarily been
described as a disease aﬀecting bone growth, joint stability,
and ligamentous laxity. In 2000 however, a form of
MED resulting from a mutation in one of the type IX
collagen genes (COL9A3) was as associated with a mild
myopathy [54]. This initial observation was followed by
the recognition that some forms of PSACH-MED resulting
from CTD-COMP mutations may also present with mild
myopathy [53, 55]( T a b l e s1 and 2).
4.1.1. MED Resulting from Mutations in COL9A3 (EDM3).
In an MED family with a COL9A3 mutation patientsJournal of Biomedicine and Biotechnology 7
presented with proximal muscle weakness (despite predom-
inantly distal skeletal changes) and mildly elevated levels of
creatine kinase (CK; an indicator of muscle degeneration
and myopathy). These individuals tired easily and a muscle
biopsy from one aﬀected family member showed mild
myopathicchangescharacterisedbyamildvariabilityinﬁber
size [54]. Interestingly, there is no evidence that type IX
collagen is expressed in skeletal muscle as a fully functioning
trimer [66, 67]. Therefore, it is tempting to speculate that
the pathology in this case arises from an abnormal enthesis
(the tendon to bone attachment site where type IX collagen
is expressed). This may also explain why no gross myopathic
changes were seen in the muscle biopsy from the patient,
which would be the case if a muscle speciﬁc structural
protein was mutated. Our recent analysis of a CTD-COMP
mutant mouse model provided evidence in support of this
hypothesis.
4.1.2. PSACH-MED Resulting from Mutations in COMP
(EDM1). MED-COMP patients with a CTD-COMP muta-
tion and an associated myopathy were described in 2003
by Jakkula et al. [53]. They suﬀered from muscle weakness
from 3 years of age and had mildly elevated CK levels;
however a muscle biopsy was not performed at the time. In
2005, a further two CTD-COMP mutations were reported
by Kennedy et al. [55]( Table 2). The onset of the disease was
early and included muscle weakness, fatigue, and diﬃculty
rising from the ﬂoor, in comparison to the patient reported
by Jakkula; the CK levels were also with normal limits. A
biopsy of the patients’ muscle showed no variability in ﬁber
size, however, scattered basophilic and small atrophic ﬁbers
were noted, indicating a mild myopathy [55]. Inconclusive
dataexistswithrespecttotheexpressionofCOMPinskeletal
muscleandtendon[69,70];thereforeweanalysedaknock-in
mousemodelcarryingaCTD-COMPmutationtodetermine
the pathomolecular mechanisms of PSACH-MED related
myopathy.
4.1.3. Myopathy in Knock-In Transgenic Mouse Model of
PSACH/MED. We have recently reported the clinical phe-
notype and investigated the pathology of PSACH-MED
associated myopathy using a transgenic mouse model with
a T585M COMP mutation in the C-terminal domain
of COMP [71]. We detected COMP protein in skeletal
muscle and in the tendons and ligaments of wild type
and mutant mice, conﬁrming that it is expressed in all
of these tissues. Mice carrying the T585M CTD-COMP
mutation experienced a progressive muscle weakness even
though histological evidence of myopathy was found only
at the myotendinous and perimysial junctions. The collagen
ﬁbril organisation was abnormal in mutant tendons and
characterised by an overall increase in ﬁber diameter with
a corresponding increase in the number of branching or
bifurcating ﬁbrils. These changes had the eﬀect of producing
thinner and more lax tendons.
COMP was expressed throughout skeletal muscle and
tendon, yet the mutation resulted in a localised myopathy
and a generalised tendinopathy. Therefore, we concluded
Force on release
at 3 weeks
Force on release
at 9 weeks
Max force achieved
at 3 weeks
Max force achieved
at 9 weeks
wt
mut T585M
mut ΔD469
0
0.2
0.4
0.6
0.8
1
1.2
[
N
]
12.6% ∗
20.7% ∗
23.3% ∗∗∗
19.3% ∗∗
26.7% ∗∗∗
Figure 5: Grip strength measurement in COMP-CTD T585M
knock-in mice and COMP-T3 ΔD469 knock-in mice at 3 weeks
of age. COMP-CTD mice were getting tired and let go of the
apparatus easier than their wild type controls, although they were
not generally weaker at 3 weeks of age, as seen by the maximum
strengths registered (n = 15) [71]. COMP D469 mice were not
getting tired and had the same maximum strength as the wild
type controls at 3 weeks of age; however, by 9 weeks they were
signiﬁcantly weaker than their wild type littermates and tired easier,
which is indicative of a mild myopathy (n = 5 ) .K e y :w t :w i l d
type, mut: homozygous for the mutation,
∗P <. 05,
∗∗P <. 01,
∗∗∗P <. 001 (independent samples t-test).
that the given myotendinous and perimysial junctions are
responsible for transmitting the forces between the tendon
and muscle ﬁbers; the myopathy was perhaps the result
of an underlying tendon problem. This ﬁnding is very
important as it may help explain the myopathy seen in MED
patients with type IX collagen gene mutations, and more
recently, with matrilin-3 mutations (Table 2). Both of these
molecules are not expressed in skeletal muscle; however, they
are present in the ﬁbrocartilage attachment point (enthesis)
between the tendon and bone. A disruption to mechanical
forces transmitted to the muscle and an altered ability
of those tissues to remodel following stress may explain
some of the musculoskeletal complications of the MED
phenotype.
To test the hypothesis that myopathy is speciﬁcally
associated with CTD-COMP mutations localised near the
potential collagen and integrin binding sites, we have
investigated a second mouse model, COMP ΔD469 knock-
in mice (T3-COMP mutation), for muscle weakness using
the experimental set-up as previously described in [71]. At
3 weeks of age we found no evidence of muscle weakness in
ΔD469 mutant mice (Figure 5); however, by 9 weeks of age
the mutant mice were weaker than their wild type littermates
and tired easier, similar to the COMP-CTD mutant mice.
This indicates that PSACH-MED COMP related myopathy
may be a mutation speciﬁc phenomenon and be related
directly to the proximity of the mutation to the potential8 Journal of Biomedicine and Biotechnology
Table 2: Patient and mutation data were obtained from the European Skeletal Dysplasia Network (ESDN reference numbers) or recent
publications, as referenced.
Reference Features Diagnosis Gene Mutation Eﬀect
ESDN 01071 – Fatigue during walking MED MATN3 D176V Potential misfolding
– Muscle disease suspected by paediatrician
ESDN 01013 – Mild proximal muscle weakness at 7 years MED COL9A2 c186G > C Exon skipping
–D i ﬃculty rising from squatting position
ESDN 01003 – Mild muscle weakness MED COL9A2 c186 + 4a > c Exon skipping
[68]
– Muscle weakness
MED COL9A2 c186 + 2t > c Exon skipping
– Suspected (unproven) muscular dystrophy
– Problems with standing up from sitting position
– Problems walking on stairs
– Biopsy:
– No morphological or histochemical changes
– No ﬁbers with central nuclei
– Variation in ﬁber size
– No degradation, regeneration, or necrosis
– ATP + CrP production from pyruvate
decreased
[68]
– Neurological evaluation for abnormal walking
MED COL9A2 c186G > A Exon skipping
pattern at 6 years
– Proximal muscle weakness lower extremities
–F a m i l ya l s oa ﬀected (father, sister, sister’s
daughter)
[54]
–P r o x i m a lm u s c l ew e a k n e s s( r e p o r t e dt ot h e
MED COL9A3 IVS2-1, G > A Exon skipping
neuromuscular clinic at 10 years)
– Mildly elevated serum creatine kinase (CK)
levels
–D i ﬃculty walking and climbing stairs from 3
years on
–D i ﬃculty rising from the ﬂoor
– Some signs of proximal muscle weakness in
family members
– Muscle biopsy: mild variability in ﬁbre size
ESDN 00385
– Some signs of mild myopathy
PSACH COMP D326Y
Potential retention
(T3 domain
mutation)
– Gower’s sign (proximal muscle weakness)
– Waddling gait
–D i ﬃculties climbing stairs
–C P Kn o r m a lJournal of Biomedicine and Biotechnology 9
Table 2: Continued.
Reference Features Diagnosis Gene Mutation Eﬀect
ESDN 00430
–R e p o r t e dt on e u r o l o g i s ta ta g e2
MED COMP E457del
Potential retention
(T3 domain
mutation)
– Diminished muscle strength in:
– Hips
– Shoulders
– Quadriceps muscle
– Feet-lifting muscles
– Diagnosed with a myopathy at 5 years
– Biopsy inconclusive
[55]
–D i ﬃculty walking at 2.5 years
MED COMP D605N Potential misfolding
(CTD mutation)
– Muscle weakness
– Tired easily
–D i ﬃculty getting up from sitting
–C Kl e v e l sn o r m a l
– EMG and nerve conduction velocities normal
– Biopsy:
– Mild myopathy,
– No variability in ﬁbre size
– Scattered basophilic ﬁbers
– Some small atrophic ﬁbers
[53, 55]
– Muscle weakness from 3 years on
MED COMP R718W Potential misfolding
(CTD mutation) – Referred to neuromuscular clinic at 5 years
– Mildly elevated CK levels
binding sites on COMP rather than the speciﬁc domain of
the molecule.
4.1.4. PSACH and MED: New Findings. Recently, several
PSACH and MED patients with COMP, type IX collagen,
and also matrilin-3 mutations have been reported with
muscular complications, and these patients were originally
referred to neuromuscular clinics prior to the diagnosis of
skeletal dysplasia. This seems to support our hypothesis that
mutations in T3 domain of COMP and in other structural
molecules of tendon and cartilaginous enthesis may also
result in a mild myopathy. Blood samples from the patients
showed normal or mildly increased CK levels and their
muscle biopsy showed increased number of basophilic ﬁbers,
ﬁber necrosis, and/or variability in ﬁber diameters. We
now present an updated summary of novel PSACH-MED
mutations associated with myopathic changes (Table 2).
Interestingly, some of the newly found COMP mutations
associated with a myopathy cluster in the T3 repeats of
the COMP protein. The T3 and CTD domains of COMP
can form intramolecular interactions as demonstrated by
the recent crystal structure model [72, 73]. Therefore, the
mutations that associate speciﬁcally with a myopathy may do
so due to their speciﬁc locations, possibly near a potential
collagen or integrin binding sites and/or the intramolecular
binding sites within COMP, and myopathic phenotype
may not segregate directly with the domain, but rather
with a speciﬁc location of the mutation. Type IX collagen
and matrilin-3 mutations’ association with a myopathic
phenotype may potentially be explained by the expression
of these molecules in the ﬁbrocartilaginous enthesis [33,
74]; however the pathomolecular mechanism of the muscle
complications in these cases requires further investigation.
4.2. Schwartz-Jampel Syndrome: A Direct ECM Defect. An
autosomal recessive disorder, Schwartz-Jampel syndrome
(SJS1) [75], results form mutations in the extracellular
matrixmoleculeperlecan[76].Perlecanisaheparinsulphate10 Journal of Biomedicine and Biotechnology
proteoglycan that is a major component of basement
membranes. It is expressed in cartilage, the endomysium
of skeletal muscle, the nervous system, and in basement
membranes throughout the body. It can interact with both
ﬁbroblast growth factor 2 (FGF2) and transforming growth
factor beta (TGFβ) and is believed to play a role in tissue
growth [77]. Schwartz-Jampel syndrome is characterised
skeletally by short stature, irregular epiphyses, bowed dia-
physes, general joint deformities, and coxa valga. In skeletal
muscle SJS1 manifests with myotonic myopathy and joint
contractures [78]. The onset of the disease is quite early,
from around 3 years of age, and the muscular phenotype
often precedes the skeletal abnormalities. Another aﬀected
tissue is the eye with patients often suﬀering from myopia
and a dysplasia of the eyelids [75]. Interestingly, the skeletal
symptoms of SJS1 are at least in part due to a defect in
sodium and potassium gradients in the muscle and these
may be pharmacologically corrected [79]. What is extremely
interesting is that perlecan is not a part of a voltage channel
per se, rather it is expressed in the endomysial extracellular
matrix, thus suggesting a link (perhaps mechanical) exists
betweenvoltagechannelsandsignallingandthesurrounding
ECM.
4.3. Marfan Syndrome: An Indirect Signalling Defect. Marfan
syndrome is an autosomal dominant musculoskeletal and
ocular syndrome resulting from mutations in the extracel-
lular matrix protein, ﬁbrilin-1. Fibrilin-1 is a component of
extracellular microﬁbrils that are present in many connective
tissues such as lung, skin, kidney, blood vessels, cartilage,
muscle, cornea, and tendon [80]. Marfan syndrome patients
are characterised by abnormally high stature, scoliosis,
and highly arched palate with a crowding of the teeth
[81]. The muscular component (skeletal muscle) of Marfan
syndrome has been largely ignored until relatively recently
[82]. Muscular abnormalities can include muscle hypoplasia,
hypotonia, and weakness, and some patients also have
problemswithincreasingthemusclemassuponexercise.The
hypoplasia and hypotonia possibly result from the increased
availability of TGFβ1, which is known to bind to ﬁbrilin
associatedlatentTGFβ1bindingprotein(LTBP).Thismayin
turn aﬀect the satellite cell diﬀerentiation and proliferation
[83]. Furthermore, the patients’ biopsy shows abnormal
distribution of ﬁbrilin-1 in the endomysium [82]. Recently
losartan,anantagonistofTGFβ1,hasbeenshowntoalleviate
aortic aneurysm in a mouse model of Marfan syndrome, and
it may also help to reverse the muscular symptoms of Marfan
syndrome [84]. Since the onset of muscular symptoms can
precede the bone pathology and the muscular symptoms
may soon be treatable, an early diagnosis based on muscular
phenomena may lead to better management and better
quality of life for these patients.
4.4. Camurati-Englemann Disease: A Direct Signalling Defect.
Camurati-Engelmann disease (CED), also known as pro-
gressive diaphyseal dysplasia, is an early onset autosomal
dominant skeletal dysplasia resulting in the thickening of
the diaphyseal bones, sclerosis of the skull base, and bone
pain [85]. The ﬁrst symptoms usually manifest in early
childhood and always before 30 years of age [86]. CED
is caused by mutations in transforming growth factor β1
(TGFβ1), a molecule very important in proliferation and
diﬀerentiationofmanydiﬀerentcelltypes,includingthoseof
cartilage and bone [87]. Interestingly, CED patients are often
initially referred to neuromuscular clinics with a suspicion of
muscular dystrophy. They present with an increasing muscle
weakness, easy fatigue, and a characteristic waddling gait
[88]. However, their plasma creatine kinase (CK) level (an
indicator of muscle degeneration) is usually normal or only
mildly elevated [89]. Muscle biopsies are often normal or
show nonspeciﬁc changes, with some atrophic ﬁbers (but no
group atrophy) and thickened basement membrane around
the small vessels. Some degree of perimysial ﬁbrosis (but
no endomysial ﬁbrosis) is also observed in a proportion
of patients [89]. Electromyographs (EMG) show small
action potentials indicative of a myopathy in some muscles,
especially around the pelvic girdle whereas other muscles are
normal [89]. These observations are extremely important as
muscular complications often manifest themselves prior to
the severe skeletal symptoms and some of the radiographic
features of CED may be prevented or are treatable with
corticosteroids [90]. Therefore, a muscle biopsy/assessment
at the right site combined with radiological evidence could
potentially enable better and earlier diagnosis and treatment
of these patients.
5. Summary
The mammalian musculoskeletal system is a complex system
of diﬀerent tissues and biomechanical properties. Together
these tissues enable locomotion, protect soft organs from
damage, and act as a scaﬀold for our bodies. We sometimes
forget however that all these tissues often develop together,
are in fact interconnected, and can interact with each
other, and that aﬀecting one may have an eﬀect on the
others. Understanding these intertissue relationships may
also dramatically improve the therapies and management of
certain diseases, such as the ones described in this paper.
Early detection of an asymptomatic or a mild myopathy may
leadtoanearlierdiagnosisofanunderlyingskeletaldysplasia
[88]. Identiﬁcation of the tissues aﬀected by the disease, and
a better understanding of the disease aetiology may also lead
to the alleviation of some of the disease symptoms, better
corrective surgery, and better management of the patients.
Understanding the biomechanics of the interconnected mus-
culoskeletal system may lead to better physiotherapies for
osteoarthritis and many other bone/muscle related diseases.
Therefore, a thorough and interdisciplinary investigation of
musculoskeletal diseases and tissues is required to further
our understanding of these systems and to enable better
management and a better quality of life for patients in the
future.
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